focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.295
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.17 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Sep 2020 21:17

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

Read more
11 Sep 2020 14:09

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

Read more
11 Sep 2020 12:17

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

Read more
2 Sep 2020 11:18

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Read more
2 Sep 2020 09:25

Immupharma raises £6.5m in oversubscribed placing

(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.

Read more
27 Jul 2020 17:50

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

Read more
27 Jul 2020 15:15

ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.

Read more
11 Jun 2020 16:17

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
11 Jun 2020 13:53

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Read more
14 May 2020 17:13

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

Read more
1 May 2020 09:51

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

Read more
31 Mar 2020 07:31

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

Read more
30 Mar 2020 16:18

ImmuPharma raises ?1.5m to fund development programmes

(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.

Read more
28 Feb 2020 12:06

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Read more
6 Feb 2020 15:54

ImmuPharma and Avion to proceed with Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.